News for Abivax SA Stock (ABVX)

Abivax Announces a Change to the Composition of its Board of Directors

GlobeNewsWire • Monday

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

GlobeNewsWire • 11/19/24

Abivax presents third quarter 2024 key financial information

GlobeNewsWire • 11/14/24

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

GlobeNewsWire • 11/13/24

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

GlobeNewsWire • 10/07/24

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

GlobeNewsWire • 10/03/24

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

GlobeNewsWire • 10/03/24

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

GlobeNewsWire • 09/26/24

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

GlobeNewsWire • 09/25/24

Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research • 09/13/24

Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade

Zacks Investment Research • 09/12/24

Abivax presents first-half 2024 financial results

GlobeNewsWire • 09/09/24

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

GlobeNewsWire • 08/06/24

Abivax Provides Operational and Key Program Update

GlobeNewsWire • 07/15/24

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

GlobeNewsWire • 06/04/24

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Seeking Alpha • 04/08/24

Abivax reports 2023 financial results and operational update

GlobeNewsWire • 04/02/24

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Accesswire • 02/13/24

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Business Wire • 10/26/23

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

Accesswire • 10/24/23

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

Seeking Alpha • 10/21/23

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

Accesswire • 10/20/23

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

Accesswire • 10/20/23

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Accesswire • 10/20/23

Abivax increases size of Nasdaq uplisting deal

Market Watch • 10/19/23